Ucerastat News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ucerastat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ucerastat Today - Breaking & Trending Today

Idorsia Pharmaceuticals Ltd: Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

Ad hoc announcement pursuant to Art. 53 LR Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study Idorsia ....

Switzerland General , United Kingdom , Andrewc Weiss , Jean Paul Clozel , Idorsia Ltd , Head Of Investor Relations Corporate Communications , Idorsia Pharmaceuticals Ltd , Swiss Exchange , Paul Clozel , Chief Executive Officer , Mol Genet , Vice President , Investor Relations , Pharmaceuticals Ltd ,

Press Release: Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

Press Release: Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study Ad hoc announcement pursuant to Art. ....

United Kingdom , Jean Paul Clozel , Idorsia Ltd , Press Release , Paul Clozel , Chief Executive Officer , Dow Jones Newswires ,

Idorsia Pharmaceuticals Ltd: Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - October 11, 2021Idorsia Ltd (SIX: IDIA) today announced that MODIFY, the Phase 3 study to investigate the effect of lucerastat, as ....

Switzerland General , Andrewc Weiss , Guy Braunstein , Jean Paul Clozel , Developmentat Idorsia , Idorsia Ltd , Head Of Investor Relations Corporate Communications , Idorsia Pharmaceuticals Ltd , Swiss Exchange , Global Clinical Developmentat Idorsia , Paul Clozel , Chief Executive Officer , Vice President , Investor Relations , Pharmaceuticals Ltd ,